Custom Research Examples

Reducing Inequities in Diabetes Technology Device Use Among Patients with T1D
Partner: Medtronic
T1D Exchange Program: Quality Improvement Collaborative (T1DX-QI)
Research Goal: Reducing disparities in insulin pump and CGM use for Hispanic and non-Hispanic Black patients with T1D within 12 months.
Participants: 7,700+ across 5 pediatric and 2 adult endocrinology clinics
Results: All participating clinics increased device use in Hispanic and non-Hispanic Black patients with T1D
- Median CGM use increased by 15% in Hispanic patients with T1D
- Median CGM use increased by 12% in non-Hispanic Black patients with T1D
Our Impact: Our unique expertise in driving health equity fueled the success of this study. We used these learnings to create a guide, readily available on our website, that helps providers everywhere provide more equitable care to people with diabetes.
CGM Adhesives and Skin Irritation
Partner: Dexcom
T1D Exchange Program: Registry
Research Goal: Observing skin reactions to adhesives used in CGM technology with photo documentation by participants immediately after removing the adhesive, and again 24-72 hours later.
Participants: 362 participants
Results: All participants successfully completed all steps of this study with proper application, removal, and photographic documentation of provided adhesives. Data analysis is currently in progress.
Our Impact: Through our Registry, we can invite people with T1D who are genuinely interested in research with the potential to affect the future of diabetes technology. Our Registry platform easily enables us to identify and communicate with qualified participants.
Related articles
What’s New in Dexcom’s G7 Continuous Glucose Monitor
The Dexcom G7 continuous glucose monitor (CGM) received FDA clearance in December 2022 for people with type 1, type 2,...
Delaying Type 1 Diabetes with Tzield: What’s the Process Really Like?
On November 17, 2022, the FDA approved a new drug that can delay the full onset of type 1 diabetes...
Embarrassing & Frustrating: People with Type 1 Diabetes Talk About Using Glucagon
Emergency glucagon is a life-saving medication used to treat severe hypoglycemia (low blood sugar) in people with diabetes—particularly in those...
Investigating Factors that Worsen Diabetes Care in the U.S.
“In the past two years, we’ve all been faced with multiple challenges from the COVID-19 pandemic to rising health inequities,”...
How a Person’s Race & Ethnicity Affect their T1D Care
Despite so many advancements in diabetes technology and medications over the past 30 years, the care a person receives can...
Exploring Attitudes About Autoantibody Screening
Partner: Janssen
T1D Exchange Program: Registry, Online Community, and T1DX-QI
Research Goal: Gather experiences and perspectives on autoantibody screening from adults with T1D, caregivers of biological children with T1D, and biological siblings of people with T1D.
Participants: 26 focus group participants
Results: The most commonly perceived benefit was obtaining knowledge. Anticipated emotional burden of a potentially positive screen was a frequently reported barrier. Emotions of anxiety and relief were associated with a positive and negative result, respectively. Generally, the results demonstrated that participants had little knowledge on autoantibody screening.
Our Impact: Through our network, we were able to populate this study with a variety of ages, relationships to T1D, and real-world experience with screening.
Facilitators and Barriers to Smart Insulin Pen Use
Partner: Medtronic
T1D Exchange Program: Quality Improvement Collaborative (T1DX-QI)
Research Goal: Identify key obstacles and challenges to prescribing and using smart insulin pens.
Participants: Recruited from 21 pediatric and 7 adult endocrinology clinics
Results: We successfully identified barriers and facilitators to smart insulin pen use.
- Key barriers include: lack of provider training and awareness, cost and limited insurance coverage, lack of direct patient education, cumbersome prescribing processes
- Key benefits include: Increasing dosing accuracy, improving patient dosing confidence and adherence, improving glycemic management, reporting leads to constructive conversations and reduced conflict between provider and patients, reports provide a complete picture of glucose levels, meal intake, and dosing
Our Impact: Our established clinical research system through the T1DX-QI enables us to conduct a detailed look at processes within any provider’s standard workflow. Working with more than a dozen of our participating clinics across the country means this study reached thousands of people of varying ages, ethnicities, socioeconomic status, etc. This expansive reach enables us to capture the broad list of factors affecting smart insulin pen use.